Eco Animal Health (ECO) continued to benefit from the rollout of its flagship drug Aivlosin into new markets last year. The drug is prescribed for the treatment of diseases that can have a major commercial impact on pig and poultry farmers, with the aim of reducing the level of antibiotics routinely used - perhaps overused - in animal food production. Sales of the product were up more than 27 per cent during the 12 months to March 2017, aided by the devaluation of sterling.
To continue reading, register today
to enjoy limited access to the following:
- Daily trading news
- Funds coverage
- Features on big investment themes
- Comprehensive companies coverage
- Economic analysis